Bay­er rolls out big changes; 2024's biotech IPO queue; Dupix­en­t's 'next big thing'; 23and­Me's strug­gle with dual iden­ti­ty; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

We got one short week of rel­a­tive calm be­fore head­ing in­to Q4 and full-year earn­ings, as J&J is set to kick things off in a few days. Still catch­ing up to JPM news and in­sights? Be sure to check out record­ings of our full event in San Fran­cis­co.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER